ctDNA Tracks Relapse Risk in Breast Cancer
Personalized liquid biopsy testing identified molecular residual disease months before clinical recurrence
-
1
ctDNA monitoring predicted relapse and survival outcomes in early breast cancer more accurately than standard treatment response measures.
-
2
The study followed 136 patients and analyzed nearly 1,500 plasma samples over a median follow-up of 6.5 years.
-
3
Persistence of ctDNA after neoadjuvant therapy was strongly associated with higher recurrence and death rates.
-
4
ctDNA detection often preceded clinical relapse by a median of 13.8 months, indicating its potential for early intervention.
-
5
The assay targets tumor-specific structural variants, offering greater specificity and stability for longitudinal monitoring.
